Literature DB >> 31217529

Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?

Ebony B Carter1, Alison G Cahill2, Margaret A Olsen3, George A Macones2, Methodius G Tuuli2, Molly J Stout2.   

Abstract

OBJECTIVE: Determine whether gestational age of 17-hydroxyprogesterone caproate (17-OHPC) initiation is associated with preterm birth (PTB) risk. STUDY
DESIGN: We performed a retrospective cohort study using MarketScan® data. The primary outcome was PTB < 37 weeks. Rates of PTB were compared between medication initiation at 16-21 weeks versus 21-29 weeks. The association between compliance with weekly 17-OHPC injections and preterm birth rate was tested after adjusting for potential confounding variables. RESULT: In all 3374 pregnancies met inclusion criteria. Women with an early 17-OHPC start were less likely to deliver preterm than those with a late start (aRR 0.88; 95%CI 0.79-0.97; p = 0.02). Less compliant patients receiving <25% of recommended doses had a higher PTB rate than those receiving >85% of recommended doses (aRR 1.5; 95%CI 1.2-1.7; p < 0.01).
CONCLUSION: There is an association between both early 17-OHPC initiation and compliance with reduced rates of PTB.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31217529      PMCID： PMC6890226          DOI： 10.1038/s41372-019-0401-2

Source DB:  PubMed          Journal:  J Perinatol        ISSN： 0743-8346            Impact factor:   2.521


  12 in total

1.  Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?

Authors:  Kent D Heyborne; Amanda A Allshouse; J Christopher Carey
Journal:  Am J Obstet Gynecol       Date:  2015-08-12       Impact factor: 8.661

2.  Does progesterone treatment influence risk factors for recurrent preterm delivery?

Authors:  Paul J Meis; Mark Klebanoff; Mitchell P Dombrowski; Baha M Sibai; Sharon Leindecker; Atef H Moawad; Allison Northen; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Menachem Miodovnik; Kenneth J Leveno; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  Obstet Gynecol       Date:  2005-09       Impact factor: 7.661

3.  Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?

Authors:  Helen Y How; John R Barton; Niki B Istwan; Debbie J Rhea; Gary J Stanziano
Journal:  Am J Obstet Gynecol       Date:  2007-09       Impact factor: 8.661

Review 4.  Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies.

Authors:  Brahmajee K Nallamothu; Rodney A Hayward; Eric R Bates
Journal:  Circulation       Date:  2008-09-16       Impact factor: 29.690

5.  Why the United States preterm birth rate is declining.

Authors:  Corina N Schoen; Sammy Tabbah; Jay D Iams; Aaron B Caughey; Vincenzo Berghella
Journal:  Am J Obstet Gynecol       Date:  2014-12-12       Impact factor: 8.661

6.  Practice bulletin no. 130: prediction and prevention of preterm birth.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-10       Impact factor: 7.661

7.  Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis.

Authors:  Kara B Markham; Hetty Walker; Courtney D Lynch; Jay D Iams
Journal:  Obstet Gynecol       Date:  2014-01       Impact factor: 7.661

8.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

9.  Modification of claims-based measures improves identification of comorbidities in non-elderly women undergoing mastectomy for breast cancer: a retrospective cohort study.

Authors:  Katelin B Nickel; Anna E Wallace; David K Warren; Kelly E Ball; Daniel Mines; Victoria J Fraser; Margaret A Olsen
Journal:  BMC Health Serv Res       Date:  2016-08-16       Impact factor: 2.655

10.  The Effect of Clinical Chorioamnionitis on Cesarean Delivery in the United States.

Authors:  Kerry M Bommarito; Gilad A Gross; Denise M Willers; Victoria J Fraser; Margaret A Olsen
Journal:  Health Serv Res       Date:  2016-02-03       Impact factor: 3.402
View more
  1 in total

1.  Latency of preterm hypertensive disorders of pregnancy and subsequent cardiovascular complications.

Authors:  Joshua I Rosenbloom; Dustin Stwalley; Kathryn J Lindley; D Michael Nelson; Margaret A Olsen; Molly J Stout
Journal:  Pregnancy Hypertens       Date:  2020-05-31       Impact factor: 2.899
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.